Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10

Clinical Microbiology and Infection

Volumn 21, Issue 2, 2015, Pages 148.e5-148.e7

  Sturegard E ^a   Angeby K A ^b,c   Werngren, J ^d   Jureen P ^d   Kronvall, G ^b   Giske, C G ^b   Kahlmeter, G ^e,f   Schon T ^g  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e Vaxjo Hospital   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

Drug susceptibility testing; Epidemiological cut off; Minimal inhibitory concentration; Normalised resistance interpretation; Resistance; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; RIFAMPICIN; CULTURE MEDIUM; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE; CHEMISTRY; COMPARATIVE STUDY; CULTURE MEDIUM; DRUG EFFECTS; EVALUATION STUDY; MICROBIAL SENSITIVITY TEST; PROCEDURES;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CULTURE MEDIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84923013605     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.08.021     Document Type: Article

References (10)

1. Canetti G., Froman S., Grosset J., Hauduroy P., Langerova M., Mahler H.T., et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Org 1963, 29:565-578.
2. Pfyffer G.E., Bonato D.A., Ebrahimzadeh A., Gross W., Hotaling J., Kornblum J., et al. Multicenter laboratory validation of susceptibility testing of mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric bactec 460 technique and the proportion method with solid media. JClin Microbiol 1999, 37:3179-3186.
3. Rusch-Gerdes S., Pfyffer G.E., Casal M., Chadwick M., Siddiqi S. Multicenter laboratory validation of the bactec mgit 960 technique for testing susceptibilities of mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. JClin Microbiol 2006, 44:688-692.
4. Angeby K., Jureen P., Kahlmeter G., Hoffner S.E., Schon T. Challenging a dogma: antimicrobial susceptibility testing breakpoints for mycobacterium tuberculosis. Bull World Health Org 2012, 90:693-698.
5. Kahlmeter G., Brown D.F., Goldstein F.W., MacGowan A.P., Mouton J.W., Odenholt I., et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 2006, 12:501-503.
6. Schon T., Jureen P., Giske C.G., Chryssanthou E., Sturegård E., Werngren J., et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. The J Antimicrob Chemother 2009, 64:786-793.
7. Angeby K.A., Jureen P., Giske C.G., Chryssanthou E., Sturegård E., Nordvall M., et al. Wild-type MIC distributions of four fluoroquinolones active against mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. JAntimicrob Chemother 2010, 65:946-952.
8. Jureen P., Angeby K., Sturegard E., Chryssanthou E., Giske C.G., Werngren J., et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of mycobacterium tuberculosis infections. JClin Microbiol 2010, 48:1853-1858.
9. Kronvall G., Giske C.G., Kahlmeter G. Setting interpretive breakpoints for antimicrobial susceptibility testing using disk diffusion. Int J Antimicrob Agents 2011, 38:281-290.
10. Van Deun A., Aung K.J., Bola V., Lebeke R., Hossain M.A., de Rijk W.B., et al. Rifampin drug resistance tests for tuberculosis: Challenging the gold standard. JClin Microbiol 2013, 51:2633-2640.